Fabrication of small-diameter vascular scaffolds by heparin-bonded P(LLA-CL) composite nanofibers to improve graft patency
Open Access
- 1 June 2013
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 8 (1) , 2131-2139
Abstract
The poor patency rate following small-diameter vascular grafting remains a major hurdle for the widespread clinical application of artificial blood vessels to date. Our previous studies found that electrospun poly(L-lactide-co-epsilon-caprolactone) (P[LLA-CL]) nanofibers facilitated the attachment and growth of endothelial cells (EC), and heparin incorporated into P(LLA-CL) nanofibers was able to release in a controlled manner. Hence, we hypothesized that heparin-bonded P(LLA-CL) vascular scaffolds with autologous EC pre-endothelialization could significantly promote the graft patency rate. To construct a small-diameter vascular scaffold, the inner layer was fabricated by heparin-bonded P(LLA-CL) nanofibers through coaxial electrospinning, while the outer layer was woven by pure P(LLA-CL) nanofibers. Except dynamic compliance (5.4 ± 1.7 versus 12.8 ± 2.4 × 10-4/mmHg, P < 0.05), maximal tensile strength, burst pressure, and suture retention of the composite, scaffolds were comparable to those of canine femoral arteries. In vitro studies indicated that the scaffolds can continuously release heparin for at least 12 weeks and obtain desirable endothelialization through dynamic incubation, which was confirmed by EC viability and proliferation assay and scanning electronic microscopy. Furthermore, in vivo studies demonstrated that pre-endothelialization by autologous ECs provided a better effect on graft patency rate in comparison with heparin loading, and the united application of pre-endothelialization and heparin loading markedly promoted the 24 weeks patency rate of P(LLA-CL) scaffolds (88.9% versus 12.5% in the control group, P < 0.05) in the canine femoral artery replacement model. These results suggest that heparin-bonded P(LLA-CL) scaffolds have similar biomechanical properties to those of native arteries and possess a multiporous and biocompatible surface to achieve satisfactory endothelialization in vitro. Heparin-bonded P(LLA-CL) scaffolds with autologous EC pre-endothelialization have the potential to be substitutes for natural small-diameter vessels in planned vascular bypass surgery.Keywords
This publication has 28 references indexed in Scilit:
- Development of tissue engineered vascular grafts and application of nanomedicineWIREs Nanomedicine and Nanobiotechnology, 2012
- Biofunctional Materials for Directing Vascular DevelopmentCurrent Vascular Pharmacology, 2012
- Tissue Engineering a Small Diameter Vessel Substitute: Engineering Constructs with Select Biomaterials and CellsCurrent Vascular Pharmacology, 2012
- The Anticoagulant and Antithrombotic Mechanisms of Heparin2011
- Bioengineered Vascular Grafts: Can We Make Them Off-the-Shelf?Trends in Cardiovascular Medicine, 2011
- Cell-Seeding Techniques in Vascular Tissue EngineeringTissue Engineering Part B: Reviews, 2010
- Heparin-bonded ePTFE grafts compared with vein grafts in femoropopliteal and femorocrural bypasses: 1- and 2-year resultsJournal of Vascular Surgery, 2009
- Drug releasing systems in cardiovascular tissue engineeringJournal of Cellular and Molecular Medicine, 2009
- Blood vessel replacement: 50 years of development and tissue engineering paradigms in vascular surgeryPhysiological Research, 2009
- Improving the Clinical Patency of Prosthetic Vascular and Coronary Bypass Grafts: The Role of Seeding and Tissue EngineeringArtificial Organs, 2002